Cipher Pharmaceuticals Inc. (TSE:CPH – Get Free Report) (NASDAQ:CPHR)’s stock price passed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of C$13.76 and traded as high as C$15.00. Cipher Pharmaceuticals shares last traded at C$14.17, with a volume of 89,992 shares trading hands.
Cipher Pharmaceuticals Trading Up 4.1%
The firm has a market capitalization of C$360.13 million, a price-to-earnings ratio of 12.65 and a beta of 1.29. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.59 and a quick ratio of 2.67. The firm’s 50-day simple moving average is C$13.76 and its 200 day simple moving average is C$15.73.
Cipher Pharmaceuticals (TSE:CPH – Get Free Report) (NASDAQ:CPHR) last released its earnings results on Thursday, November 12th. The company reported C$0.60 earnings per share for the quarter. The firm had revenue of C$18.08 million during the quarter. Cipher Pharmaceuticals had a return on equity of 22.74% and a net margin of 58.81%. Equities analysts expect that Cipher Pharmaceuticals Inc. will post 1.29 earnings per share for the current year.
Insider Activity
In other Cipher Pharmaceuticals news, Director Craig Mull purchased 20,000 shares of the stock in a transaction dated Friday, September 18th. The stock was bought at an average price of C$14.16 per share, with a total value of C$283,200.00. Following the acquisition, the director owned 1,009,953 shares of the company’s stock, valued at approximately C$14,300,934.48. This represents a 2.02% increase in their ownership of the stock. Insiders own 42.00% of the company’s stock.
About Cipher Pharmaceuticals
Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.
Read More
- Five stocks we like better than Cipher Pharmaceuticals
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
- Why Equinix and Digital Realty Benefit From Data Center Zoning Battles
Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
